Sensient Technologies Corp
$6.37B- Market cap
- $5.70B
- Debt
- +$709.58M
- Cash
- −$36.53M
Capital structure 89% equity / 11% debt · EV / Revenue 3.95x · EV / EBITDA 26.71x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: SXT stock price at premium vs AMGN $133.90 current versus $87.87 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Implied fair value · at SXT's multiple
Snapshot Sep 8, 11:33 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SXT FY 2025 (ended Dec 31, 2025) · AMGN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 89% equity / 11% debt · EV / Revenue 3.95x · EV / EBITDA 26.71x
Capital structure 78% equity / 22% debt · EV / Revenue 7.18x · EV / EBITDA 18.80x
AMGN carries the larger enterprise value at $263.99B against $6.37B; SXT trades on the lower EV / Revenue multiple (3.95x vs 7.18x); AMGN on the lower EV / EBITDA (18.80x vs 26.71x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Sensient Technologies Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.59x
6.84x
Net debt / EBITDA
Leverage against operating earnings
2.82x
3.57x
Cash and equivalents
Liquid reserves on the balance sheet
$36.53M
$9.13B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
INTERNATIONAL FLAVORS & FRAGRANCES INC
SXT vs IFF
COTY INC.
SXT vs COTY
ECOLAB INC.
SXT vs ECL
Ingredion Inc
SXT vs INGR
REGENERON PHARMACEUTICALS, INC.
SXT vs REGN
BIOGEN INC.
SXT vs BIIB
VERTEX PHARMACEUTICALS INC / MA
SXT vs VRTX
Gilead Sciences, Inc.
SXT vs GILD
Moderna, Inc.
SXT vs MRNA
Eli Lilly and Company
SXT vs LLY
$709.58M
$59.20B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.